Biogen Idec Inc (BIIB): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Biogen Idec ( BIIB) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.6%. By the end of trading, Biogen Idec fell $10.10 (-4.2%) to $227.39 on heavy volume. Throughout the day, 2,401,717 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,373,400 shares. The stock ranged in price between $220.08-$234.70 after having opened the day at $234.15 as compared to the previous trading day's close of $237.49. Other companies within the Health Care sector that declined today were: Infinity Pharmaceuticals ( INFI), down 39.1%, Synta Pharmaceuticals ( SNTA), down 34.0%, Affymax ( AFFY), down 18.3% and Vermillion ( VRML), down 14.1%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $56.7 billion and is part of the drugs industry. The company has a P/E ratio of 37.9, above the S&P 500 P/E ratio of 17.7. Shares are up 63.2% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Clovis Oncology ( CLVS), down 103.9%, Tesaro ( TSRO), down 35.1%, Chelsea Therapeutics International ( CHTP), down 22.3% and Flamel Technologies ( FLML), down 18.3% , were all gainers within the health care sector with Boston Scientific ( BSX) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire